BridgeBio Pharma, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Biotechnology | Market Cap: ₹13.4K Cr
- Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth in Q1 2026. - BridgeBio expects operating losses to flatten over the next two quarters due to ramping up launch activities for upcoming products.
From BridgeBio Pharma, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹68.45
Market Cap
₹13.4K Cr
P/E Ratio
204.4
Revenue Rank
Margin Rank
How does BridgeBio Pharma, Inc. rank in Biotechnology?
Compare BridgeBio Pharma, Inc. against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth in Q1 2026.
- →New patient starts and first-line share gains are accelerating, driving market momentum.
- →Attruby expected to be a $4 billion drug with potential upside, continuing growth even beyond 2032.
- →Three near-term launches—LGMD2I, ADH1, and achondroplasia—are progressing with strong commercial readiness.
- →LGMD2I entering a disease area with no approved therapy; high patient engagement predicted.
- →ADH1 market building aided by claims analysis and genetic testing identifying patients.
- →Achondroplasia launch supported by strong Phase III data and high physician awareness.
- →Market for ATTR cardiomyopathy continues to expand, with 5,000 to 6,000 new patient starts per quarter.
- →Focus on continued pipeline execution and expansion of indications to sustain long-term growth.
📈 Profitability & Margins
Rank 3- →BridgeBio expects operating losses to flatten over the next two quarters due to ramping up launch activities for upcoming products.
- →By end of 2027, the company targets transitioning to operating profit breakeven followed by sustainable cash flow positivity.
- →Attruby's net sales showed strong growth (24% quarter-over-quarter, 392% year-over-year), driving revenue increases.
- →Investments continue in launches and pipeline programs, but with disciplined OpEx management resulting in more than 50% narrowing of operating losses over five quarters.
- →The company has significant cash reserves (~$940 million) to fund operations and growth.
- →Share repurchase program authorized ($500 million) to enhance shareholder value without compromising operational funding.
- →Confident in growth trajectory supported by strong market momentum, expanded sales, and upcoming launches in LGMD2I, ADH1, and achondroplasia.
- →Attruby alone projected as a $4 billion drug with potential upside beyond 2032.
🏗️ Capital Expenditure Plans
Yes- →BridgeBio is focused on executing its current pipeline, including launches of AV H1, LGMD2I, and achondroplasia, ensuring high-quality regulatory submissions and commercial readiness.
- →The company sees significant additional opportunities by leveraging existing drug products, such as Attruby, and internal pipeline programs (ADPKD, cardiomyopathy, antibody programs).
- →BridgeBio maintains a disciplined capital approach, prioritizing investment in its own pipeline and launches rather than aggressive external acquisitions or broad dilution.
- →The Board authorized a $500 million share repurchase program as an opportunistic, additive use of capital alongside continued investment in clinical trials and launches.
- →The company intends to keep ample cash reserves to fully finance critical clinical and commercial programs, preserving financial flexibility and liquidity.
- →BridgeBio also has stakes in sister companies (e.g., Bandola Bio) for off-balance sheet R&D in genetic diseases, allowing focus on internal programs.
💰 Fundraising & Capital Structure
No- →The company currently has a strong cash position of $940.2 million, providing significant runway to fund operations, advance programs, and invest in growth.
- →There is no explicit mention of plans for new fundraising through debt or equity in the near term.
- →The results indicate a focus on financial discipline and leveraging existing resources for launches and pipeline advancement.
- →The company emphasizes preserving full financial flexibility to finance critical programs before deploying capital to share repurchases.
- →Overall, BridgeBio appears focused on internal funding and capital deployment, without announcing new external fundraising activities at this time.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Frequently Asked Questions
What were BridgeBio Pharma, Inc. Q2 FY26 results?
- Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth in Q1 2026. - BridgeBio expects operating losses to flatten over the next two quarters due to ramping up launch activities for upcoming products.
What is BridgeBio Pharma, Inc. share price analysis?
BridgeBio Pharma, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 204.4 with a market cap of $13,396. Investors should review the full earnings analysis for detailed insights.
Is BridgeBio Pharma, Inc. planning capital expenditure?
- BridgeBio is focused on executing its current pipeline, including launches of AV H1, LGMD2I, and achondroplasia, ensuring high-quality regulatory submissions and commercial readiness.
Keep BridgeBio Pharma, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.